title: CD1a-positive dendritic cell density predicts disease-free survival in papillary thyroid carcinoma.
abstract: OBJECTIVE
  Dendritic cells are common in inflammatory processes and in papillary thyroid carcinoma (PTC). Previous studies of the predictive value of S100-positive dendritic cell density for PTC outcome yielded inconsistent results. This study investigated the association of dendritic cell density and PTC recurrence based on CD1a expression.
  
  
  METHODS
  Representative slides from 56 consecutive specimens of PTC were immunostained with anti-CD1a antibodies, and dendritic cell density was analyzed by disease-free survival.
  
  
  RESULTS
  Dendritic cells were abundant in the tumoral tissue and sparse in the normal peritumoral tissue. Peritumoral dendritic cell density >1.1 cells/HPF was inversely associated with the risk of recurrence. Similar results were obtained with tumoral dendritic cell density (>12 cells/HPF), although the statistical significance was marginal.
  
  
  CONCLUSIONS
  High CD1a-positive dendritic cell density is associated with improved disease-free survival in PTC. The specificity of anti-CD1a immunostain for activated dendritic cells may explain the better outcome prediction in this study than in studies using S100 protein.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel. Electronic address: ohadhilly@yahoo.com.
authors.forename: Ohad
authors.initials: O
authors.lastname: Hilly
authors.affiliation: Department of Pathology, Rabin Medical Center, Petach Tikva, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Lea
authors.initials: L
authors.lastname: Rath-Wolfson
authors.affiliation: Department of Pathology, Rabin Medical Center, Petach Tikva, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Rumelia
authors.initials: R
authors.lastname: Koren
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel.
authors.forename: Aviram
authors.initials: A
authors.lastname: Mizrachi
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel.
authors.forename: Yaniv
authors.initials: Y
authors.lastname: Hamzany
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel.
authors.forename: Gideon
authors.initials: G
authors.lastname: Bachar
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Rabin Medical Center, Petach Tikva, Israel.
authors.forename: Thomas
authors.initials: T
authors.lastname: Shpitzer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018949:Antigens, CD1 / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002277:Carcinoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002291:Carcinoma, Papillary; D002452:Cell Count; D003713:Dendritic Cells / Q000276:immunology* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012307:Risk Factors; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018949:Antigens, CD1; D014408:Biomarkers, Tumor; C419393:CD1a antigen
keywords: CD1a; Dendritic cells; Disease free survival; Papillary thyroid carcinoma